IL22 immunoconjugates
AssigneePhilogen S.P.A.
InventorsFranziska Sophie Bootz, Dario Neri
Life of this patent
Estimating the term…
Abstract
The application relates to a conjugate comprising interleukin-22 (IL22) and an antibody molecule. The antibody molecule preferably binds an antigen associated with angiogenesis, such as the ED-A isoform of fibronectin. In particular, the application relates to the therapeutic use of such conjugates in the treatment of a disease/disorder, such as autoimmune diseases, including inflammatory bowel disease (IBD).
Claims15
A conjugate comprising interleukin-22 (IL22) and an antibody molecule, wherein the antibody molecule comprises an antigen-binding site which binds the Extra Domain-A (ED-A) of fibronectin and comprises the complementarity determining regions (CDRs) of antibody F8 set forth in SEQ ID NOs 1-6, and wherein the IL22 comprises the sequence set forth in SEQ ID NO:
- 11.
A conjugate which binds to the ED-A of fibronectin, wherein the conjugate comprises the amino acid sequence set forth in SEQ ID NO:
- 16.
A conjugate comprising IL22 and an scFv, wherein the scFv comprises an antigen-binding site which binds the ED-A of fibronectin and comprises the CDRs of antibody F8 set forth in SEQ ID NOs 1-6, and wherein the IL22 comprises the sequence set forth in SEQ ID NO:
- 11 and is linked to the N-terminus of the VH domain of the scFv via an amino acid linker.
Dependencies are inferred from the claim text.